Anthropic wades into drug discovery for neglected diseases

Introduction: when an artificial intelligence company becomes an apprentice pharmacist

An announcement made in San Francisco

On June 30, 2026, at an event held in San Francisco, Anthropic, the California company behind the conversational assistant Claude, unveiled a new tool called Claude Science. The launch came with a quieter but potentially more significant announcement for public health: the creation of an internal drug discovery program aimed at diseases that the conventional pharmaceutical industry considers too unprofitable to pursue (CNBC).

According to Eric Kauderer-Abrams, Anthropic's head of life sciences, the company wants to target "neglected diseases," a term used in medical circles to describe conditions that mostly affect poor or small populations, for which large drugmakers judge the commercial return too low to justify investment (STAT News).

Claude Science, a digital "workbench" for scientists

In practice, Claude Science is not a new artificial intelligence model, but a work environment that brings together more than 60 scientific databases, coding tools, computing power and research workflows in a single space, letting scientists analyze literature, run analyses and produce scientific figures (Reuters).

The tool runs on Anthropic's existing Claude models, notably Opus 4.8, and is designed to work locally on Linux or macOS, or through a remote machine. It is currently offered in beta to the company's paying users (Pharmaceutical Technology).

I remain cautious about this kind of splashy announcement: a platform that "unifies" existing tools is not yet a medical revolution. But the idea of channeling massive computing power toward diseases nobody wants to fund deserves credit, without tipping into hype.

Why neglected diseases remain a blind spot for the pharmaceutical industry

An economic problem before it is a scientific one

The concept of a neglected disease is nothing new: for decades it has referred to a group of conditions, often tropical or affecting low-income populations, in which major biopharmaceutical companies do not invest for lack of a sufficiently lucrative market. Jonah Cool, Anthropic's head of life sciences partnerships, explained that the company's goal is precisely to focus on the areas the commercial market ignores, while simultaneously selling its artificial intelligence tools to traditional laboratories (CNBC).

Anthropic, which describes itself as a "public benefit company," claims it can afford to choose programs based on patient benefit rather than financial return alone, a position the company states publicly (CNBC).

A bet that still needs to prove itself in the field

It should be noted, however, that Anthropic's drug discovery program is at a very early stage. A company spokesperson told CNBC: "We're at the very beginning of this work, and we'll share more as it progresses" (CNBC). It is therefore not yet clear whether Anthropic intends to carry these molecules through to commercialization.

According to STAT News, several company executives stressed how important it is for Anthropic to gain direct experience using its own tools to solve real scientific problems, rather than simply selling software to others (STAT News).

This candor about the project's uncertainty deserves recognition: too many tech companies promise miracles before producing a single clinical result. Here, at least, Anthropic admits it is "at the beginning."

A concrete demonstration: phenylketonuria as a textbook case

An example presented at the launch

During the launch demonstration, Claude planned and executed a search for a molecule capable of stabilizing a defective enzyme responsible for phenylketonuria, a rare metabolic disease. The system screened 2,200 compounds across 80 graphics processors, before narrowing the list to four candidates and producing a decision memo (Forbes).

The presenter then noted that the same triage process had been applied simultaneously to 100 rare diseases, raising the rhetorical question of why stop at 100 when the same mechanism could, in theory, handle 10,000 (Forbes).

The bigger picture: a sector in full swing

This announcement does not exist in a vacuum. Anthropic had already launched, in October 2025, a first tool called Claude for Life Sciences, followed in January 2026 by Claude for Healthcare. The company also signed, in May 2026, a $200 million partnership over four years with the Bill and Melinda Gates Foundation to accelerate research into neglected diseases such as human papillomavirus, polio and preeclampsia (The Next Web).

According to the World Health Organization, cited by The Next Web, roughly 4.6 billion people worldwide lack access to essential health services, a figure that gives a sense of the scale of the problem this kind of partnership seeks to address, even modestly.

Going from 100 to 10,000 diseases screened "in theory" still largely amounts to a marketing demonstration. The real question, which no press release can settle today, is how many of these drug candidates will survive real clinical trials over the years ahead.

What Claude Science can actually do for a researcher

A broad integration of existing scientific tools

Claude Science integrates tools that scientists already use daily, such as PubMed, Jupyter and R, to help researchers carry out multi-step research, analyze scientific literature and generate figures for their manuscripts, all from a single application (Pharmaceutical Technology).

The tool offers more than 60 functions covering fields such as genomics, structural biology, proteomics and cheminformatics, and can assist researchers with tasks such as designing a CRISPR screen, analyzing single-cell RNA sequencing, or rendering three-dimensional protein structures (Pharmaceutical Technology).

Traceability, a trust argument put front and center

Anthropic insists that every result produced by Claude Science includes traceable details allowing scientists to confirm the accuracy of the generated information, including the code, the computing environment and the conversation that led to a given result (The Star).

This emphasis on traceability is not trivial in a field where the smallest error can have serious consequences. A researcher using the tool must be able to trace back to the exact source of a result before relying on it to guide costly experimental work.

This technical transparency is probably the most reassuring element of this whole announcement. An artificial intelligence that explains how it arrived at a result is infinitely more useful, and less dangerous, than a black box that simply spits out an answer.

The commercial backdrop: Anthropic facing pharmaceutical companies

Partnerships already in place with major industry names

Anthropic is not starting from scratch in this sector. The company has already forged collaborations with several pharmaceutical heavyweights, including Novo Nordisk, AstraZeneca, Sanofi, AbbVie and Genmab, which use Claude for Life Sciences in their operations (Pharmaphorum). In May 2026, Anthropic also signed a deal with Bristol Myers Squibb to deploy Claude to more than 30,000 employees (Pharmaceutical Technology).

In April 2026, the company also acquired Coefficient Bio, a biotech specializing in drug discovery, in an all-stock transaction valued at roughly $400 million (IntuitionLabs).

A strategy that also serves the company's stock market ambitions

According to some analyses, Anthropic confidentially filed an S-1 registration statement with the Securities and Exchange Commission in June 2026, a preliminary step toward a possible landmark stock market listing, which could partly explain the company's eagerness to demonstrate concrete commercial usefulness in a high-value sector like healthcare.

This timing is probably not a coincidence: to convince future investors, demonstrating tangible clinical usefulness often carries more weight than any theoretical promise about a language model's general capabilities.

Never separate a company's public altruism from its financial calendar. A neglected-diseases initiative, launched right before a possible stock listing, also serves, quite concretely, to polish Anthropic's brand image.

The technical limits that press releases don't highlight

Success rates still far from perfect

An independent report notes that across 16 model configurations and 4,800 tested trajectories, no system managed to reliably reproduce preclinical pharmacology decisions. The best system tested, combining Claude Opus 4.8 with a complementary tool, succeeded only 59.3% of the time, compared with 55.3% for a competing GPT-5.5 model.

This kind of result is a reminder of a fact too often forgotten in media coverage of artificial intelligence applied to health: even the best current systems remain far from reliable enough to be treated as autonomous decision-makers in a field with stakes as high as drug discovery.

A useful reminder of an earlier figure

A specialized analysis recently noted that roughly 200 drugs designed with artificial intelligence were in clinical trials worldwide, with none having yet received full regulatory approval. That figure illustrates an unavoidable reality: the distance between a molecule identified by an algorithm and an approved, safe and effective drug remains immense.

Explaining artificial intelligence in healthcare requires resisting the temptation of sensationalism. No algorithm, however sophisticated, magically shortens the years of clinical trials needed to guarantee that a drug is safe for a human being.

What this means for patients with neglected diseases

Measured hope rather than a promise of miracles

For the millions of people affected by rare or neglected diseases around the world, this kind of initiative represents, at best, a measured glimmer of hope. Historically, these populations have been left behind by a pharmaceutical system organized around profitability, and any serious attempt to redirect technological resources toward them deserves to be followed closely, without premature excess enthusiasm.

It should be remembered, however, that moving from an artificial-intelligence-generated hypothesis to a treatment actually available in a pharmacy takes, in the best case, many years, including preclinical trials, then clinical trials on humans, before any authorization by the relevant regulatory agencies.

The role of philanthropic partnerships in the equation

The partnership with the Gates Foundation illustrates an interesting path: combining the computing power of technology companies with philanthropic funding to target diseases that primarily affect low- and middle-income countries. According to The Next Web, human papillomavirus alone causes roughly 350,000 deaths a year, 90% of which occur in these regions.

This kind of collaboration, if sustained over time, could offer a replicable model for other partnerships between tech giants and public health organizations, provided concrete results follow the announcements.

I prefer to talk about measured hope rather than revolution: patients with neglected diseases have too often heard grand technological promises that never materialized. Caution here is an act of respect toward them.

Competing tech players in the health-AI race

Anthropic is not alone in this space

Other tech giants are also betting on artificial intelligence applied to health, each with distinct approaches. This competition among major companies could, in the best-case scenario, collectively accelerate research into long-neglected diseases by multiplying attempts and scientific angles of attack.

But it also carries a risk of scattered efforts and unnecessary duplication of research, if each company develops its own closed tools rather than sharing more data and methodologies across competing laboratories.

The case for collaboration over pure competition

For neglected diseases in particular, open collaboration among tech companies, philanthropic foundations and public health institutions seems more promising than a purely competitive race among tech giants each seeking to dominate this new market.

The Gates Foundation partnership model, in which the tools developed are explicitly intended to become public goods accessible to all researchers, could serve as an example for other similar initiatives in the years ahead.

If artificial intelligence is really going to change the game for neglected diseases, it will be through collaboration among tech rivals, not an ego battle among billionaires each chasing their own medical crown.

The long history of neglected diseases and broken tech promises

A problem documented for decades by the WHO

The concept of a neglected tropical disease was formalized by the World Health Organization more than twenty years ago, to describe a group of roughly twenty conditions affecting more than a billion people, mostly in low- and middle-income countries. Chagas disease, leishmaniasis and schistosomiasis are among the most documented examples of this chronic pharmaceutical investment gap.

Despite decades of calls to action from organizations such as Doctors Without Borders and DNDi (Drugs for Neglected Diseases initiative), the number of new treatments approved specifically for these diseases remains extremely low each year, which gives a measure of the challenge Anthropic claims it wants to tackle with Claude Science.

Previous tech waves that disappointed

This is not the first time a technological wave has promised to solve the problem of neglected diseases. Low-cost genomic sequencing, then advanced bioinformatics, had already sparked comparable optimism around the turn of the 2010s, without those advances translating into a massive acceleration of treatments available to the most vulnerable populations.

This repeated history of partially kept technological promises justifies methodological caution toward any new announcement, however impressive its technical demonstration may be.

I have watched enough "revolutionary" tech waves in healthcare go by to know that the real test is never the conference demonstration, but the number of patients actually treated five or ten years later.

The role of regulators facing the acceleration of AI in health

Agencies struggling to keep pace

In the United States, the Food and Drug Administration has multiplied initiatives in recent years to govern the use of artificial intelligence in drug development, without yet having a complete and stable regulatory framework for tools as new as Claude Science. This regulatory uncertainty is a potential brake on the rapid market launch of any drug candidate identified by artificial intelligence.

Pharmaceutical regulation experts regularly point out that clinical validation remains a long and costly process regardless of the method used to identify a promising molecule, which mechanically limits how quickly a tool like Claude Science could produce a concrete impact on global public health.

The ethical questions of an AI that recommends treatments

Beyond regulation, the question of accountability and liability arises sharply: if an artificial intelligence recommends a drug candidate that later proves dangerous during clinical trials, the chain of responsibility among the model developer, the laboratory that used it and the human researchers remains legally unclear in most Western jurisdictions.

This relative vacuum calls for heightened vigilance from Western health authorities, who must adapt their evaluation frameworks without unnecessarily slowing down initiatives that could, over time, benefit populations largely left behind by the conventional pharmaceutical market.

I believe the West has a particular duty here: govern this technology without stifling it, because it is precisely in our advanced economies that the tools are being built that could, one day, help the poorest populations on the planet.

Comparing Claude Science to artificial intelligence tools already used in pharmacology

An already well-established practice in the industry

Using artificial intelligence for drug discovery is not Anthropic's invention. Companies such as Insilico Medicine, Recursion Pharmaceuticals and Isomorphic Labs, a subsidiary of Alphabet, have for several years been developing similar platforms, with clinical results still limited but massive investments from major pharmaceutical laboratories.

Isomorphic Labs, in particular, relies on advances from DeepMind's AlphaFold system to predict protein structures, a different but complementary technical capability to the one offered by Claude Science, which relies more on orchestrating existing scientific workflows than on a proprietary structural prediction model.

The specificity of Anthropic's approach

What potentially sets Claude Science apart from its competitors is its explicit positioning around neglected diseases, rather than the most lucrative therapeutic segments such as oncology or cardiometabolic diseases, which absorb most private investment in the artificial-intelligence-for-health sector.

This strategic choice, if it holds over time, could represent a positive signal for a sector where the logic of immediate profitability still largely dominates decisions about allocating resources to research and development.

I remain watchful of this specific point: if Anthropic maintains its focus on neglected diseases even after a possible stock market listing, that will be a far stronger signal than any technical demonstration.

Critical voices and warnings from bioethics experts

The risk of media overselling

Several researchers in bioethics and health policy have expressed reservations about the way tech companies communicate their advances in artificial-intelligence-driven drug discovery, arguing that the language used in press releases tends systematically to exaggerate the actual maturity of the results obtained.

This tendency toward media overselling is not unique to Anthropic, but it carries particular weight when it concerns vulnerable populations who could be given false hope by announcements that remain largely experimental.

The call for independent evaluation of results

Voices within the scientific community are calling for results produced by tools such as Claude Science to be subjected to rigorous, independent peer review, rather than being presented solely through demonstrations organized by the company itself at promotional events.

This demand for external validation is, according to several experts, an essential condition for the medical community and the general public to be able to objectively assess the real value of these new tools, beyond the commercial narrative that accompanies them.

I share this demand for independent validation without reservation: no company, however well-intentioned, should be the sole judge of the scientific quality of its own tools.

The potential impact on the global biomedical research ecosystem

A possible democratization of cutting-edge research

If Claude Science's promises materialize, even partially, the tool could help democratize access to cutting-edge research capabilities for university laboratories and research institutes in countries that traditionally lack the means to compete with major Western pharmaceutical laboratories.

This potential democratization is an important argument in favor of Anthropic's initiative, insofar as it could, in theory, redistribute some of the scientific power currently concentrated in the hands of a small number of Western multinational pharmaceutical companies.

The risk of increased technological dependence

Conversely, this same democratization could create a new form of technological dependence on major American artificial intelligence companies, which would then control not only the language models used daily, but also entire swaths of the global biomedical research infrastructure.

This tension between democratizing access and concentrating technological power deserves close attention, particularly from Western governments, which must ensure that their own strategic research capabilities do not become excessively dependent on a handful of private companies.

The West must stay at the forefront of this technological race, but never lose sight of the fact that excessive concentration of scientific power in a few private hands carries its own democratic risks too.

What this announcement reveals about Anthropic's long-term strategy

A company seeking to diversify its revenue streams

Anthropic is no longer content to sell access to its conversational assistant Claude to businesses and individuals. By multiplying specialized products such as Claude for Life Sciences, Claude for Healthcare and now Claude Science, the company is building a vertical diversification strategy aimed at establishing a lasting presence in high-value sectors such as health and scientific research.

This diversification also responds to strong competitive pressure, as OpenAI, Google DeepMind and other American tech giants actively fight over the same vertical markets with high commercial and symbolic potential.

The bet on a more responsible brand image

By specifically betting on neglected diseases rather than the most profitable therapeutic segments, Anthropic is also seeking to differentiate itself from its competitors in terms of brand image, leaning on its status as a "public benefit company" to position itself as a more responsible tech company than the sector's average.

This positioning, if it translates into concrete results for patients in the coming years, could constitute a lasting competitive advantage for Anthropic over rivals perceived as driven solely by short-term profit-seeking.

I cannot help but think that this diversification, however noble its stated intent, first answers a relentless business logic: making yourself indispensable across as many sectors as possible before competitors catch up.

Conclusion: an advance worth watching, not yet a victory to celebrate

A step in the right direction, with conditions

Anthropic's entry into drug discovery for neglected diseases constitutes, on paper, a positive gesture in a sector historically dominated by short-term profitability logic. The Claude Science tool, with its connections to more than 60 scientific databases, could indeed speed up certain stages of researchers' work, particularly hypothesis generation and literature analysis.

But caution remains warranted: no drug has yet been produced by this program, and the available data on the reliability of artificial intelligence systems in preclinical pharmacology show considerable room for improvement before these tools can be considered fully reliable.

What to watch in the coming months

The next indicators to watch will be the first concrete results of Anthropic's internal program on specific diseases, as well as the evolution of the partnership with the Gates Foundation on targets like preeclampsia and human papillomavirus. It will be at that point, and only at that point, that we will be able to judge whether this initiative represents a real advance for patients, or simply another clever technological demonstration.

I choose to remain a cautiously optimistic columnist on this file: lucid enough not to celebrate a victory that does not yet exist, but honest enough to acknowledge that steering the computing power of tech giants toward medicine's forgotten patients remains, all the same, news worth highlighting.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my acknowledged biases

I am a columnist and analyst, not a physician or a molecular biology researcher. I rely exclusively on specialized journalistic sources and publicly available company statements to build this commentary. I have no financial ties to Anthropic or the pharmaceutical industry, and I acknowledge a favorable bias toward technological initiatives that target populations neglected by the market, while remaining watchful of the risk of marketing overselling.

I recognize my limits: I cannot myself assess the scientific validity of the technical results announced by Anthropic, nor predict whether its drug discovery program will one day produce an approved treatment.

What I don't know and my method

I do not know which specific neglected diseases will be prioritized by Anthropic's internal program, nor over what time horizon concrete clinical results might emerge. My method consisted of cross-referencing specialized health and technology journalistic sources with the company's official statements, systematically flagging the uncertainties expressed by Anthropic itself.

Sources

Primary sources

CNBC — Anthropic launches AI drug discovery program, Claude Science — June 30, 2026

Anthropic — The Briefing: AI for Science, launch event — June 30, 2026

STAT News — Anthropic announces it will develop drugs itself — June 30, 2026

Secondary sources

Reuters — Anthropic unveils Claude Science for scientific research — June 30, 2026

Pharmaceutical Technology — Anthropic introduces its new pharmaceutical R&D tool — July 1, 2026

Forbes — A hands-on test of Anthropic's new AI workbench — June 30, 2026

The Next Web — Anthropic and the Gates Foundation partner for global health — May 15, 2026